

AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-305-671-0200.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Drug Requested: Repository Corticotropin Medications Dermatomyositis and Polymyositis

<u>PREFERRED</u>	<u>NON-PREFERRED</u>
<input type="checkbox"/> Purified Cortrophin™ Gel (repository corticotropin)	<input type="checkbox"/> Acthar® Gel (repository corticotropin) 80 USP Units/mL 5 mL multi-dose vial <input type="checkbox"/> Acthar® Gel (repository corticotropin) 40 USP Units/0.5 mL single-dose prefilled SelfJect injector <input type="checkbox"/> Acthar® Gel (repository corticotropin) 80 USP Units/mL single-dose prefilled SelfJect injector *Member must have tried and failed preferred Purified Cortrophin™ Gel and meet all applicable PA criteria below

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

Weight (if applicable): _____ Date weight obtained: _____

- **Acthar Gel single-dose pre-filled SelfJect injector is for subcutaneous administration by adults only.**

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied. Check box below for the Diagnosis that applies.

Member has diagnosis of DERMATOMYOSITIS OR POLYMYOSITIS with one of the following:

- | | |
|---|---|
| <input type="checkbox"/> Idiopathic Inflammatory Myopathy | <input type="checkbox"/> Refractory to conventional therapy or with severe organ-threatening manifestations |
|---|---|

1. Diagnosis of Idiopathic Inflammatory Myopathy, member **must** have tried and failed the therapies below WITHIN THE PAST 6 MONTHS:

- Prednisone 0.5-1 mg/kg/day for 2-4 weeks, then taper for 2 weeks
- Prednisone **MUST** have been taken **CONCURRENTLY WITH AN IMMUNOSUPPRESSIVE DRUG FOR AT LEAST 90 DAYS within the past 6 months (must note therapy tried):**

<input type="checkbox"/> Methotrexate target dose 25 mg/wk	<input type="checkbox"/> Azathioprine 2 mg/kg IBW twice daily
<input type="checkbox"/> Mycophenolate mofetil, 500 mg twice daily, increased by 500 mg/wk until 1000 mg twice daily	<input type="checkbox"/> Cyclophosphamide, 0.6-1 g/m ² IV every 4 weeks or 1-2 mg/kg/day orally, > 3months

2. For diagnosis that is refractory to conventional therapy or with severe organ-threatening manifestations, member **must** have tried and failed the therapies below WITHIN THE PAST 6 MONTHS:

- Methylprednisolone, 500-1000 mg/day IV for 1-3 days for 3 months
- Member **MUST** have had trial and failure of **ONE** of the following therapies for at least 90 days WITHIN THE PAST 6 MONTHS (**MUST** note therapy tried):

<input type="checkbox"/> IVIG, 1 g once month for 1-6 months	<input type="checkbox"/> Cyclophosphamide, 0.6-1g/m ² IV every 4 weeks or 1-2 mg/kg/day orally, > 3months
<input type="checkbox"/> Rituximab, 1000 mg repeat on day 15, or 375 mg/m ² once weekly for 4 weeks	<input type="checkbox"/> Cyclosporine A, 3.0-3.5 mg/kg per day

Medication being provided by a Specialty Pharmacy – Proprium Rx

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

*Approved by Pharmacy and Therapeutics Committee: 11/17/2013; 9/26/2024

REVISED/UPDATED/REFORMATTED: 6/15/2016; 8/25/2016; 9/22/2016; 12/11/2016; 7/30/2017; 9/25/2017; 6/21/2018; 1/9/2020; 6/16/2022; 10/26/2023; 10/15/2024